Clinical trials: Skin Toxicity
Hand Foot Skin Syndrome
Topical Cosmetic Products for Hand and Foot Syndrome
The aim of the study is to evaluate the efficacy of a dermocosmetic protocol in reducing the main cutaneous side effects that occur in palmar-plantar erythrodysesthesia syndrome in subjects with a tumor diagnosis, undergoing…
- Trial name
- NCT06586073
- Testing
- cosmetic products
- Where
- Italy
- Volunteers
- 53 people
- Sponsor
- Dermophisiologique s.r.l
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Lymphoma
- Trial name
- NCT00003269
- Testing
- sargramostim, amifostine trihydrate, cisplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Scripps Health
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
NATIENS: Optimal Management and Mechanisms of SJS/TEN
The North American Therapeutics in Epidermal Necrolysis Syndrome (NATIENS) study is a multicenter double-blind randomized controlled assessment of two arms - one of systemic immunomodulatory therapy (etanercept) and one of…
- Trial name
- NATIENS (NCT02987257)
- Testing
- Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4
- Where
- 14 sites in United States
- Volunteers
- 2 people
- Sponsor
- Vanderbilt University Medical Center
Metastatic Breast Cancer, Toxicity
PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
On March 17th, 2011, the European Commission issued a marketing authorization valid throughout the European Union for Eribulin mesylate (Halaven; Eisai Limited), for the treatment of patients with locally advanced or metastatic…
- Conditions
- Metastatic Breast Cancer, Toxicity, Neurotoxicity, Drug Toxicity
- Trial name
- NCT02864030
- Testing
- ERIBULIN MESYLATE
- Where
- 20 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Oncologia Medica dell'Ospedale Fatebenefratelli
IL-2 Induced Hypotension
Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2
The clinical use of IL-2 is currently limited by development of dose-dependent hypotension (systolic blood pressure (SBP) < 90 mm Hg).
- Trial name
- NCT00033956
- Testing
- M40403
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- MetaPhore Pharmaceuticals
Breast Neoplasms, HER2/Neu Positive
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer
This phase II trial studies the side effects and how well lapatinib ditosylate and trastuzumab work in treating older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer that has spread from where…
- Conditions
- Breast Neoplasms, HER2/Neu Positive, Geriatric Health Services
- Trial name
- NCT01273610
- Testing
- Lapatinib, Trastuzumab, laboratory biomarker analysis
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- City of Hope Medical Center
HIV Infections, Lipodystrophy
Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults
HIV lipoatrophy is a condition marked by fat loss; it occurs in many patients taking antiretroviral (ARV) therapy that includes nucleoside reverse transcriptase inhibitors (NRTIs).
- Conditions
- HIV Infections, Lipodystrophy, Metabolic Diseases, Nutrition Disorders
- Trial name
- NCT00119379
- Testing
- NucleomaxX, Tenofovir Disoproxil Fumarate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Metastatic Breast Cancer
Toxicity Markers to Trastuzumab-Deruxtecan (T-DXd) In Patients With Advanced Breast Cancer
the anti-Human Epidermal Growth Factor Receptor 2 (HER2) Trastuzumab-Deruxtecan (T-DXd) has shown impressive clinical activity in pretreated patients with metastatic breast cancer (MBC) but is also associated with a…
- Trial name
- Tox-DXd (NCT07049133)
- Testing
- T-DXd toxicity marker identification
- Where
- Italy
- Volunteers
- 84 people
- Sponsor
- European Institute of Oncology
Breast Cancer, Radiation Toxicity
Whole Breast Irradiation vs Twice Daily vs. Once Daily Accelerated Partial Breast Irradiation
This is a randomized phase III trial in women with invasive carcinoma of the breast with negative axillary nodes treated by Breast Conserving Surgery (BCS).
- Trial name
- NCT03616626
- Testing
- Once Daily APBI, Twice Daily APBI, Whole Breast Irradiation
- Where
- Egypt
- Volunteers
- 91 people
- Sponsor
- National Cancer Institute, Egypt
Advanced Lung Adenocarcinoma
Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have become standard practice for advanced non-small cell lung cancer (NSCLC) with EGFR gene mutation.
- Trial name
- NCT05204758
- Testing
- TCM Formula
- Volunteers
- 30 people
- Sponsor
- China Medical University Hospital
Dermatologic Complications, Palmar-plantar Erythrodysesthesia
Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer
RATIONALE: Pyridoxine may help prevent hand-foot syndrome caused by capecitabine in patients with cancer. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome in patients with…
- Conditions
- Dermatologic Complications, Palmar-plantar Erythrodysesthesia, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00486213
- Testing
- pyridoxine hydrochloride
- Where
- Singapore
- Volunteers
- 210 people
- Sponsor
- National Cancer Centre, Singapore
Cardiac Toxicity, Antitumor Drugs
Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients
According to the existing clinical data in our hospital, retrospective study was conducted to screen the risk factors with predictive value for TRC(trastuzumab-related cardiotoxicity) risk, and to construct the risk prediction…
- Conditions
- Cardiac Toxicity, Antitumor Drugs, Breast Cancer
- Trial name
- NCT04962425
- Testing
- Trastuzumab
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Peking University Third Hospital
Cancer, Breast, Cancer Colorectal
Interventions to Decrease Financial Toxicity
Financial distress affects 30-70% of cancer patients and describes the burden that patients experience due to the costs of care (CoC).
- Conditions
- Cancer, Breast, Cancer Colorectal, Cancer, Ovarian, Cervical Cancer
- Trial name
- P-COC (NCT05939440)
- Testing
- Proactive Cost of Care (P-COC) intervention, Usual Care
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Alabama at Birmingham
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer
RATIONALE: Pyridoxine (vitamin B6) may prevent or lessen hand-foot syndrome caused by chemotherapy. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Endometrial Cancer, Fallopian Tube Cancer
- Trial name
- NCT00245050
- Testing
- pyridoxine hydrochloride, doxorubicin HCL liposome
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer, Metastatic Breast Cancer
Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response
The metabolism of anticancer drugs is influenced by genetic variants that affect their bioavailability and toxicity. In the case of antibody-drug conjugates (ADCs), such as sacituzumab-govitecan (SG), trastuzumab-deruxtecan…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Drug-Related Side Effects and Adverse Reactions, Pharmacogenetic Variant
- Trial name
- NCT07582887
- Testing
- Sacituzumab Govitecan, Trastuzumab deruxtecan, Datopotamab Deruxtecan
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
Melanoma Stage III or IV
CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma
People who develop a type of skin cancer known as 'melanoma' are often treated with immunotherapy. The type of immunotherapy used for patients with melanoma is known as Immune Checkpoint Inhibitors (ICI).
- Trial name
- CARD-IO (NCT06605833)
- Testing
- 12-Lead ECG, Transthoracic Echocardiogram, Cardiac MRI
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Skin Toxicities
Development of Dermatology-related Quality of Life Assessment in Patients Treated With Epidermal Growth Factor Receptor (EGFR) Inhibitors
Epidermal Growth Factor Receptor Inhibitors (EGFRI) are associated with skin toxicities. Clinical experience suggests that skin toxicities interfere with health related quality of life (HRQL) and may interfere with treatment…
- Trial name
- FAST (NCT01015326)
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Northwestern University
Aging, Breast Cancer
The Value of Geriatric Assessments in Older Patients With Breast Cancer
Elderly cancer patients are a special group, often complicated by a variety of chronic diseases, which bring serious obstacles to surgery and adjuvant treatment.
- Conditions
- Aging, Breast Cancer, Chemotherapeutic Toxicity, Survival
- Trial name
- NCT03640117
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University People's Hospital
Breast Cancer
Single-dose Preoperative Partial Breast Irradiation in Low-risk Breast Cancer Patients
In this ABLATIVE-2 trial, low-risk breast cancer patients will be treated with MRI-guided single dose preoperative partial breast radiotherapy to assess the rate of pathologic complete response after an interval of six to twelve…
- Trial name
- ABLATIVE-2 (NCT05350722)
- Testing
- Single dose ablative radiotherapy
- Where
- 7 sites in Australia, Netherlands
- Volunteers
- 100 people
- Sponsor
- Amsterdam UMC, location VUmc
Breast Cancer
Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant Chemo for Advanced Breast Cancer
The purpose of this research is to test whether bacteria that normally live in the intestines play a role in fighting cancer. It is believed that the development and behavior of these immune cells may be influenced by bacteria…
- Trial name
- NCT02696759
- Testing
- Blood & Fecal Collection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Arkansas